Is Black Diamond Therapeutics, Inc. (BDTX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 18.1% / 30% | 80.5% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 18.1% / 33% | 80.5% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 18.1% / 33% | 80.4% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 18.1% / 33% | 80.5% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 18.1% / 33% | 80.4% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 100.0% | |
| Operating Margin | 28.4% | |
| Net Margin | 32.0% | |
| Return on Equity (ROE) | 22.9% | |
| Return on Assets (ROA) | 9.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$62M |
| Free Cash Flow | -$62M |
| Total Debt | $22M |
| Debt-to-Equity | 16.7 |
| Current Ratio | 8.4 |
| Total Assets | $123M |
Price & Trading
| Last Close | $2.13 |
| 50-Day MA | $2.34 |
| 200-Day MA | $2.93 |
| Avg Volume | 765K |
| Beta | 3.4 |
|
52-Week Range
$1.20
| |
About Black Diamond Therapeutics, Inc. (BDTX)
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Black Diamond Therapeutics, Inc. (BDTX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Black Diamond Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Black Diamond Therapeutics, Inc.'s debt ratio?
Black Diamond Therapeutics, Inc.'s debt ratio is 18.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 18.1%.
What are Black Diamond Therapeutics, Inc.'s key financial metrics?
Black Diamond Therapeutics, Inc. has a market capitalization of $116M, trailing P/E ratio of 5.2. The company maintains a gross margin of 100.0% and a net margin of 32.0%. Return on equity stands at 22.9%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.